EGFR and non-small cell lung carcinoma: Halmos et al., (2019) further demonstrated in the international real-world study with 228 EGFR-mutant NSCLC patients that there was no significant difference in TTF (p = 0.543) between patients who remained on afatinib ≥ 40 mg/day for the first 6 months (19.5 months; 95% CI: 13.4–not evaluable (Cho et al., 2020), who reduced dose to < 40 mg/day within the first 6 months (17.7 months; 95% CI: 14.5–21.5), and who started with afatinib ≤ 30 mg/day (19.4 months; 95% CI: 12.9-NE).